0% versus 59.6%). Readmissions rates were lower for patients who were discharged with any form of ongoing medication assisted therapy compared to those who were not (30-day all cause readmissions 18.8% versus 35.1%; 30-day opioid-related readmissions 10.1% versus 29.9%; 90-day all-cause readmissions 27.3% versus 42.7%; 90-day opioid-related readmissions 15.1% versus 33.3%). Conclusions There is a strong association between medication assisted therapy and reduced against medical advice discharge rates. Additionally, maintenance medication assisted therapy at time of discharge is strongly associated with reduced readmissions rates.Objectives Current guidelines recommend pharmacologic prophylaxis for medical patients at high risk for venous thromboembolism. We aimed to assess the benefit and safety of venous thromboembolism prophylaxis in acutely ill medical patients hospitalized. Methods Retrospective cohort study in a tertiary hospital in Israel. Patients hospitalized in medical departments with an admission lasting more than 48 hours during 2014-2017. Primary outcome 30-day mortality. Secondary outcomes 90 day incidence of pulmonary embolism, symptomatic deep vein thrombosis, and major bleeding. Propensity-weighted logistic multivariate analysis was performed. Results A total of 18890 patient-unique episodes were included in the analysis. Of them 3206 (17.0%) received prophylaxis. A total of 1309 (6.9%) died, 540/3206 (16.8%) of those who received venous thromboembolism prophylaxis and 769/15864 (4.9%) of those who did not. Prophylaxis was not associated with a reduction in mortality, multivariable-adjusted odds ratio propensity-weighted (OR) 0.99 (95% confidence interval (CI) 0.84 - 1.14). 142 patients (0.7%) developed venous thromboembolism, 44/3206 (1.4%) of those who received prophylaxis and 98/15864 (0.6%) of those who did not. Prophylaxis was not associated with reduction in venous thromboembolism in the whole cohort, multivariable-adjusted propensity-weighted OR 1.09 (95% CI 0.52 - 2.29). Prophylaxis was associated with an increase in major bleeding (multivariable-adjusted propensity-weighted OR 1.24, 95% CI 1.04 -1.48) CONCLUSION The current practice of routinely administering venous thromboembolism prophylaxis to medically ill patients considered at high risk for thrombosis, resulted in a high risk for bleeding without a clear clinical benefit, and should be reassessed.Background Aspirin is often prescribed for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) however, recent randomized trials (RCTs) have challenged this practice. Despite this, aspirin is commonly recommended for high risk primary prevention. We tested the hypothesis that aspirin is more efficacious for the primary prevention of ASCVD, as the baseline risk increases. Methods RCTs that compared aspirin to control for primary prevention and evaluated ASCVD (composite of myocardial infarction and ischemic stroke) and major bleeding were included. Rate ratios (RR) and 95% confidence intervals (CI) were calculated. A regression analysis was performed using the ASCVD event rate in the control arm of each RCT as the moderator. Results Twelve RCTs were identified with 963,829 patient years of follow-up. Aspirin was associated with a reduction in ASCVD (4.7 versus 5.3 events per 1,000 patient years; RR 0.86; 95% CI 0.79-0.92). There was increased major bleeding among aspirin users (2.5 versus 1.8 events per 1000 patient years, RR 1.41 95% CI, 1.29-1.54). Regression analysis found no relationship between the log rate ratio of ASCVD or major bleeding and incidence of ASCVD in the control arm of each RCT. Conclusion Aspirin is associated with a reduction in ASCVD when used for primary prevention; however, it is unlikely to be clinically significant given the increase in bleeding. More importantly, aspirin's treatment effect does not increase as ASCVD risk increases as many hypothesize. There is no suggestion from this data that use of aspirin for higher risk primary prevention patients is beneficial.Facial paralysis is the most common cranial nerve paralysis and the majority of these are idiopathic. Idiopathic facial paralysis, or Bell's palsy, typically presents acutely, affects the entire face, may be associated with hyperacusis, decrease in lacrimation, salivation or dysgeusia, and typically resolves spontaneously. The diagnosis of idiopathic facial paralysis is made after a thorough history and physical examination to exclude alternative etiologies and follow-up to ensure recovery of facial function. Atypical presentation, recurrent paralysis, additional neurologic deficits, lack of facial recovery in 2-3 months, and/or history of head and neck or cutaneous malignancy are concerning for alternative causes of facial paralysis requiring workup. The erroneous use of the eponym Bell's palsy to refer to all causes of facial paralysis, regardless of the history and presentation, may result in cognitive errors including premature closure, anchoring bias, and diagnosis momentum. Hence, we recommend replacing the eponym Bell's palsy with idiopathic facial nerve paralysis.We emulated instances of open traumatic brain injuries (TBI) in a maritime disaster. New Zealand rabbit animal models were used to evaluate the pathophysiological changes in open TBI with and without the influence of artificial seawater. New Zealand rabbits were randomly divided into 3 groups. https://www.selleckchem.com/products/1-azakenpaullone.html Control group consisted of only normal animals. Animals in TBI and TBI + Seawater groups underwent craniotomy with dura mater incised and brain tissue exposed to free-fall impact. Afterward, only TBI + Seawater group received on-site artificial seawater infusion. Brain water content (BWC) and permeability of blood-brain barrier (BBB) were assessed. Reactive oxygen species levels were measured. Western blotting and immunofluorescence were employed to detect apoptosis-related factors Caspase-3, Bax and Bcl-2; angiogenesis-related factors CD31 and CD34; astrogliosis-related factor glial fibrillary acidic protein (GFAP); potential neuron injury indicator neuron-specific enolase (NSE). Hematoxylin & eosin, Masson-trichrome and Nissl stainings were performed for pathological observations.